{"id":5544,"date":"2019-07-25T14:33:39","date_gmt":"2019-07-25T09:03:39","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5544"},"modified":"2021-07-24T12:57:28","modified_gmt":"2021-07-24T07:27:28","slug":"pharma-happenings-for-pfizer-freenome-lilly","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-freenome-lilly","title":{"rendered":"Baqsimi wins FDA nod for Hypoglycemia; Freenome captures USD 160M; FDA approval for Ruxience for leukaemia"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><strong>FDA Approves Eli Lilly&#8217;s Baqsimi, the first treatment for Severe Hypoglycemia<\/strong><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">The U.S. FDA gave its approval to <strong>Baqsimi nasal powder<\/strong>, for the treatment of <strong>Severe Hypoglycaemia<\/strong> in patients with diabetes ages four and older. Baqsimi is a powder administered into the nose and is the <strong>first non-injectable<\/strong> emergency treatment for severe episodes of hypoglycaemia. The nasal powder comes with a single-use dispenser and works by stimulating the liver to increase the levels of stored glucose into the blood-stream. It is noteworthy that Eli Lilly\u2019s Baqsimi can be administered to an unconscious person as it does not need to be inhaled. <br>Severe Hypoglycaemia occurs when the blood sugar levels of a person fall to a level where the patients become unconscious. Usually, <a href=\"https:\/\/www.delveinsight.com\/report-store\/severe-hypoglycemia-market\">hypoglycaemia <\/a>affects people already living with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-nephropathy-market\">diabetes <\/a><\/strong>and are on insulin treatment. The Hypoglycaemia treatment is entirely dependent on the severity of the hypoglycaemia episode. Mild-to-moderate hypoglycaemia is easily self-treated with the oral intake of rapid-acting carbohydrates such as a glucose drink, tablets, or snacks, whereas, severe hypoglycaemia necessitates external help. Monitoring of blood glucose levels becomes important to regulate to prevent the risk of hypoglycaemia. <br>Pharma giants such as <strong>Zealand Pharma<\/strong>, <strong>Xeris Pharmaceuticals<\/strong>, and others are involved in developing effective therapies for<a href=\"https:\/\/www.delveinsight.com\/report-store\/severe-hypoglycemia-epidemiology-forecast\"> <strong>Severe Hypoglycaemia treatment<\/strong><\/a><strong>.<\/strong> <strong>According to DelveInsight, the global severe hypoglycaemia therapeutics market is expected to increase by the major drivers such as rising prevalent population, technological advancements, and upcoming therapies in the forecast period (2019-28). <\/strong><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Freenome nets USD 160 Million to accelerate blood-based colorectal cancer program <\/strong><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Freenome<\/strong>, a San Francisco based biotech company announced a successful closure of its <strong>USD 160 Million Series B financing, <\/strong>totalling up to <strong>USD 238 Million <\/strong>till date. The Financing led by existing investors RA Capital Management and Polaris Partners, along with the new ones including Perceptive Advisors, Roche Venture Fund, Kaiser Permanente Ventures and the American Cancer Society\u2019s BrightEdge Ventures, as well as funds and accounts advised by T. Rowe Price Associates. <br>Freenome is a pioneer in developing <strong>the most comprehensive &#8216;multiomics&#8217; platform for early cancer detection through a routine blood draw. <\/strong>The company plans to use the funds and proceeds to further develop its platform for early detection of colorectal cancer through blood tests, expand its laboratory infrastructure and software to support its continued growth. It is also thinking of submitting to the US FDA and Centres for Medicare &amp; Medicaid Services (CMS) for the validation of its colorectal cancer screening platform under the Parallel Review Program.<br><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/colorectal-cancer-crc-market\">Colorectal cancer is the third most common cancer in the United States<\/a>. <\/strong>At present, the Colorectal Cancer treatment depends on the type and stage of cancer, possible side effect any therapy can lead to, and patient\u2019s preference for any particular therapy. The <strong>Colorectal cancer <\/strong>therapy majorly includes surgical resection in the early stages of cancer development followed by effective therapies which include radiation therapy, targeted therapy, immunotherapy, and chemotherapy.<br>Some of the FDA approved marketed drugs available in the Colorectal Cancer therapy market are <strong>Capecitabine <\/strong>(Xeloda), <strong>Fluorouracil <\/strong>(5-FU), <strong>Irinotecan <\/strong>(Camptosar), <strong>Oxaliplatin <\/strong>(Eloxatin), Trifluridine\/tipiracil (Lonsurf), <strong>Capecitabine <\/strong>(Xeloda) and many more. Talking about the emerging therapies, the Colorectal Cancer pipeline is very dynamic. The positive outcomes of some of the rare candidates such as <strong>Arfolitixorin <\/strong>(Isofol Medical AB), <strong>Napabucasin <\/strong>(Boston Biomedical), <strong>SGM-101 (<\/strong>Surgimab), <strong>GM102 <\/strong>(GamaMabs Pharma), <strong>Vicriviroc <\/strong>(Merck Sharp and Dohme), <strong>Promitil <\/strong>(Lipomedix), and others during the clinical trialss assures a significant positive shift in the Colorectal Cancer market size. <strong>DelveInisght estimates that the dynamics of <a href=\"https:\/\/www.delveinsight.com\/report-store\/severe-hypoglycemia-epidemiology-forecast\">Colorectal Cancer market <\/a>is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies and incremental healthcare spending across the world.<\/strong> <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Pfizer\u2019s Rituximab biosimilar, Ruxience receives FDA approval, for lymphoma leukaemia<\/strong><\/h4>\n\n\n\n<p class=\"has-background has-text-align-left has-very-light-gray-background-color\">Pfizer\u2019s Ruxience, a biosimilar to rituximab received FDA approval recently for the treatment of adult patients with <strong>non-Hodgkin\u2019s lymphoma<\/strong> (NHL), <a href=\"https:\/\/www.delveinsight.com\/report-store\/b-cell-chronic-lymphocytic-leukemia-market\"><strong>chronic lymphocytic leukaemia<\/strong> <\/a>(CLL), and <strong>granulomatosis with polyangiitis<\/strong> (GPA) and microscopic polyangiitis (MPA). The approval from the FDA came after the results after successful outcomes of the clinical trials REFLECTIONS B3281006, in which the efficacy, safety and immunogenicity, pharmacokinetics and pharmacodynamics of <strong>RUXIENCE <\/strong>were evaluated. <strong>The trials revealed no difference in the efficiency of the Ruxience as compared to Rituxan in the patients suffering from CD20-positive low-tumour-burden follicular lymphoma.<\/strong> The approval of Ruxience, which promises to improve access and <a href=\"https:\/\/www.delveinsight.com\/blog\/the-era-of-gene-therapy-and-the-billion-dollar-tag\/\">affordability of cancer treatment<\/a>, is third such approval of the company for oncology biosimilar. Pfizer\u2019s Ruxience, however, is not the biosimilar, which received the approval from the FDA. The first biosimilar to Rituximab, <strong>Truxima <\/strong>got approved in December last year. <br><strong>Rituximab <\/strong>(Rituxan), a drug developed by IDEC Pharmaceuticals, received approval from the FDA, at first, to accelerate B-cell Non-Hodgkin&#8217;s Lymphoma therapy market in 1997. However, its use improved the treatment outcomes in patients with CLL and many other ailments. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA Approves Eli Lilly&#8217;s Baqsimi, the first treatment for Severe Hypoglycemia The U.S. FDA gave its approval to Baqsimi nasal powder, for the treatment of Severe Hypoglycaemia in patients with diabetes ages four and older. Baqsimi is a powder administered into the nose and is the first non-injectable emergency treatment for severe episodes of hypoglycaemia. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5545,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[137,704,17539,427],"industry":[17225],"therapeutic_areas":[17240,17228],"class_list":["post-5544","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cancer","tag-fda","tag-hypoglycemia","tag-oncology","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Baqsimi wins FDA nod for Hypoglycemia; Freenome captures USD 160M<\/title>\n<meta name=\"description\" content=\"Pfizer\u2019s Ruxience, a biosimilar to rituximab received FDA approval recently for the treatment of adult patients with non-Hodgkin\u2019s lymphoma (NHL)...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-freenome-lilly\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Baqsimi wins FDA nod for Hypoglycemia; Freenome captures USD 160M\" \/>\n<meta property=\"og:description\" content=\"Pfizer\u2019s Ruxience, a biosimilar to rituximab received FDA approval recently for the treatment of adult patients with non-Hodgkin\u2019s lymphoma (NHL)...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-freenome-lilly\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-25T09:03:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/09021041\/BUSINESS-BLOG.png\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Baqsimi wins FDA nod for Hypoglycemia; Freenome captures USD 160M","description":"Pfizer\u2019s Ruxience, a biosimilar to rituximab received FDA approval recently for the treatment of adult patients with non-Hodgkin\u2019s lymphoma (NHL)...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-freenome-lilly","og_locale":"en_US","og_type":"article","og_title":"Baqsimi wins FDA nod for Hypoglycemia; Freenome captures USD 160M","og_description":"Pfizer\u2019s Ruxience, a biosimilar to rituximab received FDA approval recently for the treatment of adult patients with non-Hodgkin\u2019s lymphoma (NHL)...","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-freenome-lilly","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-07-25T09:03:39+00:00","article_modified_time":"2021-07-24T07:27:28+00:00","og_image":[{"width":750,"height":410,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/09021041\/BUSINESS-BLOG.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-freenome-lilly","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-freenome-lilly","name":"Baqsimi wins FDA nod for Hypoglycemia; Freenome captures USD 160M","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-freenome-lilly#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-freenome-lilly#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/09021041\/BUSINESS-BLOG.png","datePublished":"2019-07-25T09:03:39+00:00","dateModified":"2021-07-24T07:27:28+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Pfizer\u2019s Ruxience, a biosimilar to rituximab received FDA approval recently for the treatment of adult patients with non-Hodgkin\u2019s lymphoma (NHL)...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-freenome-lilly"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-freenome-lilly#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/09021041\/BUSINESS-BLOG.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/09021041\/BUSINESS-BLOG.png","width":750,"height":410,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/09021041\/BUSINESS-BLOG-300x164.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hypoglycemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Oncology<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Hypoglycemia<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 25, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jul 25, 2019 2:33 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma News ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5544"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5544\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5545"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5544"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5544"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}